TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20708904
Drug: Intramuscular levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular levetiracetam (500mg, 5ml)
Study: 20708904
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam
Study: 18368612
Drug: Agonist pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist pharmacotherapy (specific agonists not detailed)
Study: 12577189
Drug: Pamidronate 30
Normalized name: pamidronate 30 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 30 mg intravenously every 3 months, combined with 1000 mg calcium and 1000 IU vitamin D per day.
Study: 12577189
Drug: Pamidronate treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate treatment.
Study: 2200894
Drug: 1988-1989 trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1988-1989 trivalent split-antigen influenza vaccine
Study: 23306361
Drug: Three injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injection techniques
Study: 7970440
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at 140 micrograms kg‐1 min‐1
Study: 7970440
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion combined with low-level dynamic exercise
Study: 26903399
Drug: 1.0 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/day of oral 17β estradiol (E2) for 3 months
Study: 26903399
Drug: 50 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg/day of transdermal 17βE2 for 3 months
Study: 21211205
Drug: Single intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular 25 mg etanercept injection
Study: 21211205
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml compound betamethasone
Study: 14974908
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol and 0.5 mg norethisterone
Study: 1601148
Drug: hCG administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administered 1 day after criteria (Group 2, n = 84)
Study: 31201809
Drug: Sacrospinous ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacrospinous ligament suspension
Study: 25016216
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care treatment model for depression
Study: 11231366
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin containing 1 mg of folic acid for four weeks
Study: 2656096
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g iv for three doses/8 h)
Study: 26850798
Drug: Teucrium polium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teucrium polium (250 mg q6h for the first 3 days of menstruation for two cycles)
Study: 25656524
Drug: 25-hydroxycholecalciferol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxycholecalciferol (3 mg of Hidroferol, 180,000 IU)
Study: 18480689
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/d (2 x 10 mg)
Study: 15837245
Drug: TAXUS stent
Normalized name: Taxus baccata fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAXUS stent (insulin-requiring subgroup)
Study: 8522681
Drug: Cilazapril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (angiotensin-converting enzyme inhibitor)
Study: 1884962
Drug: Hourly intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly intravenous injections of 100 mg of cimetidine along with a continuous nasogastric infusion of a liquid antacid at the rate of 0.5 ml per minute
Study: 23602205
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg elemental Zn/day)
Study: 11063377
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with autologous stem cell transplantation
Study: 24894084
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT)
Study: 19327952
Drug: Sequential Compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Compression Devices (SCDs)
Study: 12891533
Drug: Daily lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lysine acetylsalicylate (aspirin) 160 or 300 mg/day
Study: 8678279
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg mepivacaine without epinephrine
Study: 26400955
Drug: Neuromuscular training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular training (NMT) group performing an injury prevention programme as a warm-up 3 times weekly for 12 weeks
Study: 17668348
Drug: Cocaine injection
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine injection (0.5 mg/kg)
Study: 10192753
Drug: PPS i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPS i.v. (50 mg)
Study: 31620939
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing lozenges (2 lozenges/day after brushing for 3 months with a 3-month washout)
Study: 23971720
Drug: Berberis aristata/Silybum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day after washout
Study: 16179098
Drug: Carboplatin/vinorelbine every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/vinorelbine every 4 weeks as first-line treatment
Study: 6510544
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin injections
Study: 21246848
Drug: Nobex (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nobex (intramuscular injection)
Study: 18261664
Drug: Hylan injections
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan injections
Study: 15722306
Drug: Sub‐Tenon's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub‐Tenon's block (STB) with 3 ml of 2% lidocaine and hyaluronidase
Study: 15722306
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia (TOP) with proxymetacaine 0.5% and amethocaine 1% eye drops
Study: 12651660
Drug: Anesthetic Conserving
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic Conserving Device (ACD) at 8 L/min FGF
Study: 12651660
Drug: Circle system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circle system with 1‐, 1.5‐, 3‐, and 6‐L/min FGFs
Study: 12651660
Drug: Low‐flow circle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐flow circle system (1.5‐ and 1‐L/min FGFs)
Study: 9215287
Drug: tiratricol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiratricol (24 micrograms/kg twice daily)
Study: 19747069
Drug: Oxybutynin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin IR 10 mg
Study: 11110737
Drug: Galantamine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (24 mg)
Study: 11110737
Drug: Galantamine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (32 mg)
Study: 9308074
Drug: Clonidine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (maximum daily dose 0.600 mg)
Study: 9308074
Drug: Mianserin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (maximum daily dose 90 mg) and Carbamazepine (maximum daily dose 400 mg)
Study: 8334029
Drug: 24,25-dihydroxy vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24,25-dihydroxy vitamin D3 (24,25(OH)2D3) (daily dose of 15 micrograms)
Study: 8334029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1,25(OH)2D3 and 24,25(OH)2D3
Study: 15334791
Drug: Glimepiride and
Normalized name: glimepiride and pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride and Metformin
Study: 26367325
Drug: Interdisciplinary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary therapy (4 weekly exercise sessions, 1 weekly group therapy session, 1 weekly nutritional education session)
Study: 26367325
Drug: Interdisciplinary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary therapy
Study: 24425846
Drug: No PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PRP gel (Control)
Study: 10192750
Drug: Mibefradil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (50 mg once daily for 1 week)
Study: 2182945
Drug: Diethylstilbestrol diphosphate
Normalized name: Diethylstilbestrol Diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol diphosphate (DES‐DP) plus vindesine (VND) 3 mg/m2 intravenously on days 8, 15, and 22 (group B)
Study: 29504499
Drug: Quadrupling inhaled
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrupling inhaled glucocorticoids (increase by a factor of 4)
Study: 29504499
Drug: Non-quadrupling group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-quadrupling group (same self-management plan without dose increase)
Study: 29504499
Drug: Quadrupling inhaled
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrupling inhaled glucocorticoids
Study: 27041524
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for 28 weeks
Study: 24450858
Drug: Idelalisib, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib, 150 mg twice daily
Study: 18198305
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (LCD, 890 kcal/d supplement diet until 15% weight loss, then weight maintenance)
Study: 7664860
Drug: Oral flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flurbiprofen alone
Study: 2651176
Drug: Bacampicillin suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin suspension, given twice daily, 40 mg/kg body weight for 10 days
Study: 2651176
Drug: Amoxycillin suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin suspension, given three times daily, 40 mg/kg body weight for 10 days
Study: 12891310
Drug: Ramipril (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (starting dose 2.5 mg in group 1 and 5 mg in group 2, increased to 10 mg daily over 8 weeks)
Study: 12891310
Drug: Ramipril (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (group 1: gradual regimen starting at 2.5 mg; group 2: more active regimen starting at 5 mg)
Study: 10472219
Drug: Metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.15 mg kg‐1 i.v.
Study: 1670442
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with no immediate injection of enoxaparin (Group I, 65 patients)
Study: 1670442
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 20 mg of enoxaparin one hour after the onset of anaesthesia (Group II, 61 patients)
Study: 28319467
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1 g
Study: 9602870
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcipotriol and betamethasone valerate after 2 weeks of calcipotriol monotherapy
Study: 7997001
Drug: Day-care treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-care treatment
Study: 22325733
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (active control)
Study: 30523659
Drug: Hybrid intervention
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid intervention combining exergaming and physical therapy, 90 minutes twice a week for 12 weeks
Study: 23614897
Drug: FM containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM containing 10(6) cfu LG2055/g
Study: 23614897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 cfu LG2055/g)
Study: 14670810
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg orally 4 times daily)
Study: 17688720
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluid (group 1)
Study: 11578293
Drug: Intravenous crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous crystalloid based on body-weight (group 2)
Study: 9631990
Drug: Fluconazole 300
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 300 mg
Study: 2146875
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (2 g/kg/month)
Study: 21329776
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) vaccination (2 μg/dose)
Study: 21329776
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) vaccination (10 μg/dose)
Study: 11101487
Drug: Fructooligosaccharides (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructooligosaccharides (20 g powder/d)
Study: 21484237
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of dexamethasone (DEX)
Study: 8832535
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of hydrocortisone (HCO)
Study: 30572837
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg tramadol
Study: 24931567
Drug: MSDC-0160 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSDC-0160 (150 mg once daily)
Study: 22818063
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg (T20 mg)
Study: 22818063
Drug: Tadalafil 40
Normalized name: tadalafil 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 40 mg (T40 mg)
Study: 17311545
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GH replacement therapy)
Study: 1643912
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenge (MIC)
Study: 1194144
Drug: Inspiratory elastic
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory elastic load (12.1 cmH2O/l)
Study: 31363878
Drug: CCTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA with iodixanol (270 mg I/mL), scanned with 100 kV, reconstruction by AIDR
Study: 31363878
Drug: CCTA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCTA with iopromide (370 mg I/mL), scanned with 120 kV, reconstruction by filtered back projection
Study: 15228830
Drug: Somatostatin analogue
Normalized name: Somatostatin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analogue (Sandostatin 300 microgram subcutaneously/day in three divided doses)
Study: 15228830
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods (nil per orum, total parenteral nutrition, antibiotics, skin and wound care, control of sepsis)
Study: 11097669
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with 1 mg morphine
Study: 8477148
Drug: l-alpha-glyceryl-phosphorylcholine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-alpha-glyceryl-phosphorylcholine (alpha GPC)
Study: 8477148
Drug: ST200 (acetyl-l-carnitine)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST200 (acetyl-l-carnitine)
Study: 2948256
Drug: Pindolol (2.5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5-7.5 mg, administered gradually by mouth)
Study: 18197911
Drug: NT-proBNP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP level >or=2220 pg/mL
Study: 10072664
Drug: Mosapramine addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapramine addition to neuroleptic treatment
Study: 1790543
Drug: Topilene (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topilene (generic formulation) cream
Study: 1790543
Drug: Diprolene (innovator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprolene (innovator formulation) cream
Study: 28495411
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied intraorally and extraorally with a 660-nm and 810-nm laser, respectively, at 200 mW for 10 seconds, 2 J, 1.5 J/cm2 and 7 J/cm2, repeated 2 times per week for 3 weeks.
Study: 28495411
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side received laser simulation instead of actual laser therapy.
Study: 21748445
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration (group A)
Study: 19487639
Drug: Weekly incontinence
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly incontinence
Study: 7953032
Drug: Daily Living
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Living Programme (DLP)
Study: 7714303
Drug: Nortriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (75 mg/day)
Study: 2649118
Drug: Haloperidol 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.05 mg/kg/day
Study: 2649118
Drug: Haloperidol 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.025 mg/kg/day
Study: 27029707
Drug: Tailored high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored high-dose oral vitamin D supplementation (T)
Study: 27029707
Drug: Tailored high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored high-dose oral vitamin D supplementation (T) after switching from C
Study: 25212095
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (3 mg caffeine/kg body mass)
Study: 25212095
Drug: Placebo energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo energy drink (0 mg caffeine/kg body mass)
Study: 22370839
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus casei and Bifidobacterium breve), administered three times a day for an average treatment duration of 5.06±2.18 days
Study: 22370839
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered three times a day for an average treatment duration of 5.49±3.17 days
Study: 18269776
Drug: Pemetrexed 400‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 400‐600 mg/m2 and epirubicin 60‐90 mg/m2
Study: 12091596
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly subcutaneous epoetin beta treatment
Study: 7901636
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (2.4 mg retinol) and iron (60 mg elemental iron)
Study: 2832202
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (before treatment)
Study: 27813716
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied on the right side (diode laser 660 nm, 40 mW, 1 min, 2.4 J of total energy)
Study: 27813716
Drug: Nonirradiated mini-implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonirradiated mini-implants (control group)
Study: 24023757
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pravastatin for 3.2 years
Study: 12925453
Drug: CYP3A4-MET statin
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP3A4-MET statin (atorvastatin, lovastatin, simvastatin, cerivastatin) with clopidogrel
Study: 30251616
Drug: Individual placement
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual placement and support (IPS) for 6 months in addition to treatment as usual (TAU)
Study: 29074815
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care + Hyperbaric Oxygen Therapy (SC+HBOT)
Study: 24818336
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 200,000 IU ulinastatin in 100 mL of 0.9% saline given over one hour every 12 hours for 5 days
Study: 24818336
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 200,000 IU ulinastatin
Study: 9506875
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg
Study: 19151299
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of meloxicam and gabapentin